Page last updated: 2024-12-07

taurohyodeoxycholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Taurohyodeoxycholic acid (THDCA) is a bile acid found in the bile of pigs. It is a conjugate of hyodeoxycholic acid with taurine. THDCA is synthesized in the liver from cholesterol and is released into the bile. It plays a role in the digestion and absorption of fats. THDCA has also been shown to have anti-inflammatory and anti-cancer properties. It is studied for its potential therapeutic uses in treating a variety of conditions, including inflammatory bowel disease, liver disease, and cancer.'

taurohyodeoxycholic acid: a biliary acid used for the prevention and therapy of gallstones and related symptoms [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119046
CHEMBL ID270516
CHEBI ID139138
MeSH IDM0222170

Synonyms (25)

Synonym
2958-04-5
ccris 6480
taurohyodeoxycholic acid
2-(((3alpha,5beta,6alpha)-3,6-dihydroxy-24-cholan-24-yl)amino)ethanesulfonic acid
ethanesulfonic acid, 2-(((3alpha,5beta,6alpha)-3,6-dihydroxy-24-oxocholan-24-yl)amino)-
CHEBI:139138
CHEMBL270516 ,
taurine hyodeoxycholate
2-[[(4r)-4-[(3r,5r,6s,8s,9s,10r,13r,14s,17r)-3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
thdca
d6v086emme ,
unii-d6v086emme
bdbm50375591
AC-34551
n-(3alpha,6alpha-dihydroxy-5beta-cholan-24-oyl)-taurine
taurine, n-(3.alpha.,6.alpha.-dihydroxy-5.beta.-cholan-24-oyl)-
ethanesulfonic acid, 2-(((3.alpha.,5.beta.,6.alpha.)-3,6-dihydroxy-24-oxocholan-24-yl)amino)-
2-((4r)-4-((3r,5r,6s,9s,10r,13r,14s,17r)-3,6-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
Q27276185
MS-29281
DTXSID10952061
3,6-dihydroxy-n-(2-sulfoethyl)cholan-24-imidic acid
HY-114360
CS-0083750
AKOS040756031

Research Excerpts

Overview

Taurohyodeoxycholic acid is a natural 6 alpha-hydroxylated bile acid. It is an apparent hydrophilicity intermediate between those of tauroursodeoxyCholic and taurocholic acids.

ExcerptReferenceRelevance
"Taurohyodeoxycholic acid is a natural 6 alpha-hydroxylated bile acid with an apparent hydrophilicity intermediate between those of tauroursodeoxycholic and taurocholic acids. "( Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat.
Angelico, M; Baiocchi, L; Della Guardia, P; Franchitto, A; Gaudio, E; Nistri, A, 1994
)
2.13

Toxicity

ExcerptReferenceRelevance
" No adverse effects or dose-related abnormalities were observed in the reproductive performance of either sex; no death or evidence of teratogenicity in fetuses were also observed."( Reproductive toxicity of taurohyodeoxycholic acid.
Feletti, F; Germogli, R; Tripodi, AS, 1993
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
bile acid taurine conjugateA bile acid conjugate resulting from the formal condensation of a bile acid with the amino group of taurine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)24.20000.02372.52598.9000AID324923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (46.15)18.2507
2000's6 (23.08)29.6817
2010's5 (19.23)24.3611
2020's3 (11.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.62 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]